

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain; depression	Indoleamine 2,3-dioxygenase 1 (IDO1)	<p>Rat studies suggest inhibiting IDO1 could help treat pain and depression. Arthritic rats showing pain-induced depressive behaviors had higher hippocampal Idol levels than nonarthritic rats. In the same rats, hippocampal injection of the IDO1 inhibitor 1-methyl-D-tryptophan (D-1MT) decreased nociceptive and depressive behaviors compared with vehicle injection. Next steps include optimizing the dosing of an IDO inhibitor in animal models.</p> <p>NewLink Genetics Corp.'s D-1MT is in Phase I/II testing to treat solid tumors.</p> <p>INCB24360, an IDO inhibitor from Incyte Corp., is in Phase II testing to treat solid tumors.</p> <p>SciBX 5(29); doi:10.1038/scibx.2012.763 Published online July 26, 2012</p>	<p>Patent application filed covering use in pain and depression; available for licensing from the Massachusetts General Hospital Office of Research Ventures and Licensing</p>	<p>Kim, H. <i>et al.</i> <i>J. Clin. Invest.</i>; published online July 2, 2012; doi:10.1172/JCI61884</p> <p>Contact: Jianren Mao, Harvard Medical School, Boston, Mass. e-mail: jmao@partners.org</p>